Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 16/20 | 0.44 |
| ▸ | HTR2C | P28335 | 16/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799374 | 1.00 | HTR2A (0.44) | HTR2AHTR2CSLC6A2L3MBTL1MEN1 | |
| SCHEMBL8319596 | 1.00 | HTR2A (0.44) | HTR2AHTR2CSLC6A2L3MBTL1MEN1 | |
| SCHEMBL799520 | 0.89 | SIGMAR1 (0.37) | HTR2AHTR2CSLC6A2L3MBTL1MEN1 | |
| SCHEMBL799397 | 0.88 | HTR2A (0.54) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL2743279 | 0.83 | HTR2A (0.33) | HTR2AHTR2CSLC6A2L3MBTL1MEN1 | |
| SCHEMBL21729531 | 0.82 | HTR2A (0.42) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL25040613 | 0.78 | HTR2A (0.34) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL12583415 | 0.78 | HTR2A (0.34) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL8318217 | 0.77 | SLC6A2 (0.51) | HTR2AHTR2CSLC6A2L3MBTL1MEN1 | |
| SCHEMBL8318258 | 0.77 | SLC6A2 (0.51) | HTR2AHTR2CSLC6A2L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2020112872-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| EP-1643998-B1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, TAC3, TACR1 | HTR2A 882/4885HTR2C 671/4885SLC6A2 181/4885 |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | HTR2A 4335/4885HTR2C 4192/4885SLC6A2 4171/4885 |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, TAC3, TACR1 | HTR2A 882/4885HTR2C 671/4885SLC6A2 181/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | HTR2A 2197/4885HTR2C 2280/4885SLC6A2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.